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ARTICLE OPEN
Pre-clinical evaluation of a P. berghei-based whole-sporozoite
malaria vaccine candidate
António M. Mendes 1, Isaie J. Reuling 2, Carolina M. Andrade 1, Thomas D. Otto 3,6, Marta Machado1, Filipa Teixeira1,
Joana Pissarra1, Nataniel Gonçalves-Rosa 1, Dolores Bonaparte1, João Sinfrónio1, Mandy Sanders3, Chris J. Janse4, Shahid M. Khan4,
Chris I. Newbold3, Matthew Berriman3, Cynthia K. Lee5, Yimin Wu5, Christian F. Ockenhouse5, Robert W. Sauerwein2 and
Miguel Prudêncio 1
Whole-sporozoite vaccination/immunization induces high levels of protective immunity in both rodent models of malaria and in
humans. Recently, we generated a transgenic line of the rodent malaria parasite P. berghei (Pb) that expresses the P. falciparum (Pf)
circumsporozoite protein (PfCS), and showed that this parasite line (PbVac) was capable of (1) infecting and developing in human
hepatocytes but not in human erythrocytes, and (2) inducing neutralizing antibodies against the human Pf parasite. Here, we
analyzed PbVac in detail and developed tools necessary for its use in clinical studies. A microbiological contaminant-free Master Cell
Bank of PbVac parasites was generated through a process of cyclic propagation and clonal expansion in mice and mosquitoes and
was genetically characterized. A highly sensitive qRT-PCR-based method was established that enables PbVac parasite detection and
quantiﬁcation at low parasite densities in vivo. This method was employed in a biodistribution study in a rabbit model, revealing
that the parasite is only present at the site of administration and in the liver up to 48 h post infection and is no longer detectable at
any site 10 days after administration. An extensive toxicology investigation carried out in rabbits further showed the absence of
PbVac-related toxicity. In vivo drug sensitivity assays employing rodent models of infection showed that both the liver and the
blood stage forms of PbVac were completely eliminated by Malarone® treatment. Collectively, our pre-clinical safety assessment
demonstrates that PbVac possesses all characteristics necessary to advance into clinical evaluation.
npj Vaccines            (2018) 3:54 ; doi:10.1038/s41541-018-0091-3
INTRODUCTION
Despite a recent decrease in malaria-related mortality, the goal of
eradication remains distant and is unlikely to be achieved in the
absence of an effective vaccine against this disease. Whole-
sporozoite (WSp) vaccination approaches have been shown to
elicit sterile protection against malaria both in rodent models and
in humans. Protection mediated by such vaccine candidates relies
on the immune responses elicited by the parasite’s pre-
erythrocytic forms, following administration of live sporozoites
to the mammalian host. WSp-based malaria immunization
generally employs P. falciparum (Pf) sporozoites rendered safe
by radiation or genetic attenuation, or by concomitant prophy-
lactic administration of antimalarial drugs acting on the erythro-
cytic stage of the parasite1.
The ﬁrst draft genome of Pb ANKA (PbA) was published in
2005,2 followed by further sequencing, re-assembly and annota-
tion of what has since constituted the reference PbA genomic
sequence.3 Comparisons of the PbA genome sequence with that
of the canonical reference Pf clone 3D74 revealed that a high
percentage of the proteins predicted for the former parasite have
orthologs in the latter, as well as the near absence of
polymorphisms within the genomes of Pb isolates.5 The relative
similarity between the genomes of Pb and human-infective
Plasmodium spp., Pb’s non-pathogenicity to humans, the ability
of Pb sporozoites to infect various types of hepatic cells and cell
lines, the availability of rodent models to study Pb infection
in vivo, and Pb’s amenability to genetic modiﬁcation, have made
this parasite one of the preferred models for the investigation of
Plasmodium infection and the analysis of Plasmodium gene
function.
Among the many achievements that Pb parasites have enabled,
they have been instrumental in the development of current WSp
malaria vaccine candidates. In fact, protection conferred by
radiation attenuated sporozoites (RAS), which are unable to
develop inside liver cells, was initially demonstrated in mice using
irradiated wild-type Pb parasites,6 paving the way for the
development of Pf RAS vaccine candidates.7–9 Sporozoites can
also be attenuated by deletion of speciﬁc genes, leading to the
parasite’s developmental arrest in the liver,10 an immunization
strategy that is awaiting clinical validation.11,12 Typically, although
not always,13 genes targeted for deletion in Pf to generate
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genetically attenuated parasites (GAP) are homologs of genes
primarily identiﬁed in rodent parasites as critical for their hepatic
development.14 Finally, the administration of Pf sporozoites under
a chemoprophylactic regimen of an antimalarial drug (CPS), which
kills the parasite’s blood forms, and has also been shown to confer
long lasting protection in humans,15,16 was equally based on
previous studies in rodents, employing Pb sporozoites adminis-
tered concomitantly with a prophylactic dose of chloroquine.17
Collectively, the studies outlined above illustrate the pivotal role
played by wild-type and genetically modiﬁed Pb in the ﬁeld of
WSp malaria vaccination. However, a signiﬁcant advance occurred
recently, with a genetically modiﬁed Pb parasite, termed PbVac,
proposed as a WSp vaccine against human malaria in and of itself,
rather than as a surrogate for Pf-based vaccination or a tool to
assess immune responses elicited by Pf vaccines. PbVac has been
engineered to express the immunodominant Pf antigen, the
circumsporozoite protein (PfCS), ﬂanked by the Pb pre-erythrocytic
stage-speciﬁc promoter, UIS4 (upregulated in infective sporozoites
4).10 PbVac infects and develops in human hepatocytes but not in
human red blood cells, and is capable of eliciting both Pb/Pf cross-
species and PfCS-dependent immune responses against the
human-infective Pf parasite.18
The results outlined above warrant the clinical evaluation of
PbVac. However, such an endeavor demands an encompassing
characterization of the PbVac parasite as well as the development
and/or adaptation of methodologies ensuring its safety for human
use. Here, we describe the establishment of a microbiological
contaminant free and genetically stable PbVac parasite Master Cell
Bank (MCB), as well as a highly sensitive qRT-PCR based
methodology for detection and quantiﬁcation of PbVac parasites
in tissues and organs. Parasites from this MCB were used in an
extensive array of biodistribution, toxicology, and drug sensitivity
assays that ascertain its amenability to clinical use. Collectively,
these results paved a way for the evaluation of PbVac in Phase I/IIa
clinical trials aimed at assessing its safety, tolerability, and
protective efﬁcacy in humans.
RESULTS
Generation and analyses of a PbVac master cell bank
MCB were constructed for the parental wild-type Pb and the
cloned PbVac parasites, as described in the Methods section (Fig.
1). Analyses of fecal pellets, oral swabs, and fur swabs of SPF Balb/
c mice employed throughout the study conﬁrmed the absence of
microbiological contamination (Table S1). MCB samples were
analyzed and found to be free of adventitious virus, as well as
mouse- and human-infective microbiological contaminants (Table
S2). The entire genomes of the Pb and PbVac parasites collected
prior to and following cyclical propagation were subsequently
sequenced, in order to extensively characterize the genetic
differences between the wild-type and the genetically modiﬁed
Pb parasites, as well as any changes that might have been
introduced during the propagation procedure. The read depth per
genome was at least ×38 coverage, which was subjected to de
novo assembly and compared to the most recent genome
assemblies for Pb and Pf. PbVac sequencing results conﬁrmed a
single insertion site of the PfCS gene and its ﬂanking sequences in
the PbP230p gene present in chromosome 3 of the Pb genome
(Fig. 2) and showed that no additional Pf genetic material is
present in the transgenic parasite’s genome. De novo assembly of
the different samples revealed no large rearrangements or
deletions and no copy number variations were found between
the transgenic and the reference sequences, except for the UTR of
PbUIS4. No differences were detected between the PbVac
sequences prior to and after cyclical propagation and a single
base change was detected between the wild-type and transgenic
lines, which is consistent with the known overall Plasmodium
mutation rate.19 Overall, these results establish the full genomic
sequence of PbVac and conﬁrm the insertion of the PfCS gene in
the parasite’s expected genomic locus. To conﬁrm the stability of
this insertion, PbVac MCB parasites underwent 8 passages through
SPF Balb/c mice and 2 passages through mosquitoes, and the
insert region of blood stages of the the PbVac parasite collected
from selected mice was sequenced (Fig. S1). Our results
demonstrate that the PfCS gene remains correctly inserted in
Fig. 1 Construction of PbVac MCB. PbVac parasites underwent 3 consecutive cyclic passages through mice and mosquitoes prior to clonal
expansion in a ﬁnal batch of mice. Blood collected from these mice was aliquoted and stored to constitute the PbVac MCB, and tested for
microbiological contamination. In parallel, the parental wild-type Pb parasite underwent a similar procedure and was subsequently aliquoted
and stored. The whole genomes of both parasites were sequenced before and after cyclical propagation and clonal expansion. SPF-certiﬁed
BALB/cByJ mice were used in all steps of the procedure
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the expected locus throughout this procedure of mechanical
passage (data not shown), indicating that no loss if genetic
material is expected to occur during the 2 passages through mice
and 1 passage through mosquitoes that must precede parasite
administration in a clinical setting.
High-sensitivity qRT-PCR detection and quantiﬁcation of PbVac
parasites
Clinical evaluation of the PbVac vaccine candidate requires close
monitoring of the highly unlikely possibility of appearance of
blood stage parasitemia in human subjects. To this end, we
established a quantitative real-time PCR (qRT-PCR) assay that
could adequately detect PbVac in different tissues, including
human blood samples. The linear range of ampliﬁcation of the
TaqMan qRT-PCR and the assay’s limit of detection were
determined employing tenfold serial dilutions of a plasmid
encoding a fragment of the Pb 18S rRNA gene (Fig. 3a). The
assay’s limit of detection was calculated at 0.0001 copies of target
standard plasmid per PCR reaction, with linearity observed
between 0.1 and 1010 copies of plasmid, and the efﬁciency of
the assay was calculated at 113%. The dynamic range of the assay
for detection of PbVac was initially determined in mouse blood
using genomic DNA extracted from serial dilutions of synchro-
nized PbVac-infected blood cultures (Fig. 3b). The calculated limit
of detection of the assay was 0.006 parasites/μl of blood, with
linearity observed between 6.1 and 61,674 parasites/μl of blood.
Agarose gel electrophoresis analysis conﬁrmed the presence of a
single DNA band corresponding to the expected size of the
amplicon of interest (134 bp) (Fig. 3b). The assay was applied to
the detection of PbVac in human blood, yielding a limit of
detection of 0.05 parasites/μl of blood. Analysis of the reaction
products by agarose gel electrophoresis conﬁrmed the presence
of a single 134 bp DNA band (Fig. 3c). Our results show that this
assay constitutes a highly sensitive, precise, and reproducible
assay to detect and quantify PbVac on a small volume of whole
blood with minimal pre-analytical processing to support clinical
care and malaria vaccine research. Our results also establish 18S
rRNA as a reliable target for a highly sensitive qRT-PCR assay,
which allows the detection of as few as 0.05 parasites/μl of human
blood.
Distribution of PbVac in rabbit tissues
Given the promiscuous nature of Pb parasites, safety requirements
demand an investigation of the biodistribution of PbVac in a
Fig. 2 Whole-genome sequencing of wild-type Pb and PbVac parasites before and after cyclical propagation and clonal expansion. a Insertion
site of the construct in the P230p locus of Pb’s chromosome 3. b The PfCS gene is covered by reads from the PbVac parasite lines, showing that
it is contained in the genome of the genetically modiﬁed parasite. c Artemis screenshot showing the copy number variation of the PbUIS4
gene in the wild-type Pb and PbVac parasites (top) and the “not properly paired” reads of the transgenic parasite lines (bottom). For each
panel, the coverage plot is represented at the top and the mapped reads are shown at the bottom. Black: wild-type Pb prior to cyclic
propagation; gray: wild-type Pb after cyclic propagation and clonal expansion; blue: PbVac prior to cyclic propagation; red: PbVac after cyclic
propagation and clonal expansion
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suitable animal model. Our previous report established that PbVac
infects and develops in NZW rabbit hepatocytes but not in NZW
rabbit red blood cells, mimicking the expected behavior of this
parasite in humans.18 Thus, NZW rabbits were selected as the
animal model of choice to assess the tissue distribution of PbVac
in vivo. To this end, NZW rabbits were infected by the bites of 75
PbVac-infected A. stephensi mosquitoes (Fig. 4a) and killed 1 h,
48 h, and 10 days after infection. Bladder, blood, brain, epidermis,
eye, heart, kidney, liver, lung, lymph node, bone marrow, muscle,
spleen¸ subcutis, ovary, and testes samples were collected at each
time point of euthanasia and processed for RNA extraction,
followed by cDNA synthesis and qRT-PCR analysis using the
methodology described above. RNA quality was conﬁrmed by gel
electrophoresis analysis of brain, heart, and lung samples (Fig. S2).
The detection sensitivity of the 18S-Pb gene in the standard
plasmid was shown to be unaffected by the presence of cDNA
from brain, heart, and lung tissues (Fig. S3A). Additionally, effective
extraction of parasite RNA in the presence of rabbit tissues was
conﬁrmed by qRT-PCR and agarose gel electrophoresis analyses
(Fig. S3B). Our qRT-PCR analysis of organ samples collected 1 h
after sporozoite administration revealed the presence of parasite
DNA in the subcutis, epidermis, and lymph nodes at, or proximal
to, the site of administration, whereas at 48 h post-infection (hpi),
the parasite was detected in the epidermis and subcutis, as well as
in the liver. Following the qRT-PCR analysis, all samples were
analyzed by agarose gel electrophoresis. A band of the expected
fragment size (134 bp) was observed for the samples yielding a
positive signal on the qRT-PCR analysis. No parasites were
detected in any of the organs collected 10 days post-infection
(dpi) (Fig. 4b, c). Overall, our results show that the tissue
biodistribution of PbVac follows a pattern compatible with the
safety of its administration to humans and with the elicitation of a
pre-erythrocytic immune response, as parasites are detected near
the site of administration at 1 and 48 h after injection, as well as in
the liver at the latter time point. Importantly, parasites are absent
from any tissues 10 days after administration, indicating that the
parasites are fully eliminated between 2 and 10 days after
injection.
Toxicological analyses of PbVac administration to rabbits
In order to evaluate possible toxic effects of PbVac administration
to a non-permissive host, a large toxicology study was conducted
in NZW rabbits. The main study employed 40 animals subjected to
5 exposures to 97 non-infected or PbVac-infected mosquitoes,
killed three (acute phase) or 28 (recovery phase) days after the last
application of the mosquitoes (Fig. 5a). “Vaccine take” was
conﬁrmed by ELISA assessments of antibodies against PbCS and
PfCS at different points after parasite administration (Fig. 5b, c). At
in-life cage side observations, all animals showed normal water
and food consumption patterns, and regular excretions of urine
Fig. 3 PbVac parasite detection and quantiﬁcation by high-sensitivity qRT-PCR. Standard curves (top), Ct values (middle), and gel
electrophoresis analysis (bottom) following qRT-PCR ampliﬁcation of a 134 bp fragment of the PbVac 18S ribosomal gene in serial dilutions of
a plasmid containing that fragment (a), of the PbVac parasite in mouse blood (b), and of the PbVac parasite in human blood (c). Dots indicate
the average CT value and bars indicate the standard deviation obtained for at least three biological replicates
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and feces. No effects of PbVac administration on clinical
observations were noted during or after vaccination. In general,
the body weights of individual rabbits showed some minor
variations, which were correlated to blood sampling or vaccination
and were considered to reﬂect stress during these processes.
Animals recovered fast from the loss in body weight and quickly
returned to their weight before the handlings. Overall, no
signiﬁcant body weight loss or gain was observed, indicating
the tolerability of the test article (Fig. 5d). Body temperature
remained within limits (no fever, deﬁned as a temperature greater
than 40 °C, was recorded) shortly after vaccination and throughout
the next day. No increase in body temperature was observed 6
and 24 h after immunization. Rather, as a consequence of the
sedation all rabbits experienced a decrease in body temperature
6 h after administration, which returned to normal 24 h later (Fig.
5e). Ophthalmological examination of the rabbits in the acute and
recovery groups 1 day prior to their necropsies (day 58 and day
83, respectively) revealed no abnormalities. The analyses of serum,
plasma and EDTA blood samples revealed transient trends in
clinical chemistry, coagulation, and hematology parameters over
time. The changes observed in these parameters were within the
range of normal values and standard deviations were similar
across groups within the study and thus considered non-adverse.
Creatinine phosphokinase and lactate dehydrogenase levels on
day 0 were increased and were above the normal range in both
treated and control groups, which is attributed to handling and
stress.20
There were no premature decedents in the study and animals
were killed on day 59 (acute groups) or 84 (recovery groups), as
planned. At necropsy, macroscopic examinations of the external
surface of the body, all oriﬁces, injection sites, the cranial, thoracic,
and abdominal cavities and their contents were performed. No
abnormalities were observed in the animals in the acute or
recovery phase groups regarding fur, skin, and body openings. On
the injection site, only very minimal skin reactions were visible
3 days after application of the mosquitoes. No enlarged lymph
nodes nor abnormalities in kidneys, lungs, heart, liver, brain,
reproductive organs, and other organs were found. In one female
rabbit from the infected recovery group, some very slight
hematomas were observed in the skin at the injection site. In
Fig. 4 PbVac tissue biodistribution in NZW rabbits. a PbVac administration to rabbits by mosquito bite. Left: a circular area of ~10 cm diameter
of the rabbit ﬂank was shaved prior to exposure to mosquitoes. Middle: a container with 100 mosquitoes was placed on the shaved ﬂank of
the sedated animal and taped to the skin. Right: the mosquitoes were allowed to feed on the sedated animals for 15 min. b, c Gel
electrophoresis analysis of products of qRT-PCR ampliﬁcation of a 134 bp fragment of the PbVac 18S ribosomal gene in various organs of male
(b) and female (c) rabbits at different time points after parasite administration. Orange highlights correspond to organs where PbVac was
detected. The numbers correspond to the number of animals where the parasite was detected in a particular organ/the number of animals for
which that organ was analyzed. Three biological replicates, each including one male and one female NZW rabbit, were employed per time
point
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the same animal, a very large gall bladder with abnormal shape
was found, as well as gas formation in the gut, a cyst with clear
ﬂuid in one of the ovaries, and a slightly smaller brain. The
histopathology did not reveal further insights for these ﬁndings,
which were therefore considered non-related. A female rabbit
from the uninfected recovery group and a female rabbit from the
infected recovery group each had small cysts on one ovary.
Finding cysts in the ovaries of these rabbits is expected for this
species and age. Similar incidence in the control and treated
groups indicate this is not likely an effect of PbVac, so the ﬁnding
was considered non-related to PbVac. No clinically relevant
differences in organ weights and no gross lesions were observed
macroscopically. There was no PbVac-related alteration in the
prevalence, severity, or histologic character of incidental micro-
scopic ﬁndings recorded at histopathological examinations. No
PbVac-related morphologic alterations were observed on day 59
(acute groups) or day 84 (recovery groups).
Drug sensitivity of liver and blood stage PbVac parasites
Balb/c mice were used to assess sensitivity of PbVac parasites to
the commonly used antimalarials chloroquine, Coartem®, and
Malarone® in vivo. Our results showed that both Malarone® and
Coartem® completely eliminated blood stage parasites when
treatment was initiated either when parasites became detectable
or at 1.5% parasitemia (Table 1). Chloroquine treatment also
abolished blood infection in both cases but recrudescence was
observed when treatment was initiated when parasitemia reached
1.5% (Table 1). Collectively, our results show that both Malarone®
and Coartem® can be employed to effectively eliminate PbVac’s
blood forms in the very unlikely event of human blood stage
infection by this parasite.
Because Malarone® is the prefered drug to use in the context of
controlled human malaria infection (CHMI) studies and is able to
clear liver stage parasites, we selected this drug to investigate its
effect on PbVac liver infection. Our results showed that Malarone®
treatment completely abolished hepatic infection, measured 46 h
after sporozoite injection, unlike the untreated control mice, which
displayed signiﬁcant liver parasite loads (Fig. S4). These results
show that Malarone® effectively eliminates PbVac from hepatic
cells, in the unlikely event that they might persist in the liver
following administration to human subjects. This effect is
potentially due to Atovaquone, one of the active compounds of
Malarone®, which is well known to kill hepatic stage Pb
parasites.21,22
DISCUSSION
The clinical evaluation of vaccine candidates intended for human
use, including WSp malaria vaccines, must meet strict regulatory
requirements that ensure, to the fullest extent possible, the safety
of the human subjects enrolled in their assessment. This study
shows a comprehensive pre-clinical study of PbVac, obtaining the
tools necessary for its use in clinical studies and revealing the
evidence of its safety in non-permissive human hosts.
The ﬁrst report of the use of Pf RAS in humans dates from 1973
and involved the administration of immunizing parasites by the
bites of several hundred mosquitoes7. Since then, numerous
clinical trials employing Pf RAS administered either by mosquito
bite,23 subcutaneous or intradermal administration,24 or intrave-
nous inoculation8,25,26 have been carried out. Likewise, the CPS
immunization protocol has been evaluated in the clinic with
parasites administered by mosquito bites,15 by intradermal
injection,27 or direct venous inoculation.28 All of these clinical
studies adhered to the regulations in place at the time when they
were conducted, and all employed Pf, a malaria parasite whose
natural hosts are human beings, as the immunizing agent. In this
context, our recently proposed strategy for WSp vaccination,
which relies on a genetically modiﬁed Pb parasite for immuniza-
tion of humans against malaria,18 poses a whole new set of
challenges that we have now addressed.
WSp vaccine candidates tested in the clinic have relied on
human-infective Pf parasites, administered in the context of CHMI
experiments.29 As Pf infections occur commonly in the ﬁeld, the
delivery of Pf sporozoites to humans in a clinical context can be
considered a “natural” infection by a human-infective organism.
Pf-based WSp vaccine candidates employed in these experiments
are generated in mosquitoes infected by membrane feeding on
parasite cultures maintained in in vitro conditions. However, the
clinical evaluation of a rodent Plasmodium-based vaccine candi-
date constitutes uncharted territory and therefore demands a
stringent pre-clinical safety assessment process. PbVac is not only
a genetically modiﬁed organism but also one that requires
passage through rodents before infection of mosquitoes to
produce sporozoites. In order to enter clinical development, such
parasites must be of known genetic identity and with no
extraneous DNA and drug-resistance markers. PbVac was con-
structed using a double crossover homologous recombination
method that ensures the permanent and stable introduction of
the PfCS gene into the Pb genome.30 The GIMO method of genetic
modiﬁcation employed further ensures the generation of a
mutant parasite expressing a heterologous protein free of drug-
resistance genes.31 In order to be used in humans, PbVac must not
only be genetically stable but also microbiological contaminant
free. Blood stage Pb parasites develop normally into merozoites
in vitro but cannot egress from the erythrocyte without additional
mechanical shear stress,32 hampering the infection of mosquitoes
by standard membrane feeding assay technologies used for Pf,
and demanding that the production of PbVac sporozoites for
vaccination must rely on the infection of mosquitoes through
biting PbVac-infected mice. We have thus created a MCB of PbVac,
following the parasite’s cyclic propagation in SPF Balb/c mice and
Table 1. PbVac parasite clearance following administration of clinically relevant schedules and doses of selected drugs to mice
Drug Schedule (hpi) Dose in humans (w) Dose in mice (w/W) Parasitemia at treatment initiation Day of parasite clearance
t= 0/6/24/48 t= 0–600mg t= 0–64mg/kga Onset 3
Chloroquine t= 6/24/48–300mg t= 6/24/48–32mg/kga ~1.5% 2
Coartem® t= 0/8/24/36/48/60 80mg ART 8.4 mg/kg ARTa Onset 3
480mg LMF 50mg/kg LMFa ~1.5% 3
Malarone® t= 0/24/48 1 g ATV 25mg/kg ATVb Onset 3
400mg PRG 10mg/kg PRGb ~1.5% 3
hpi hours post-infection, ART artemether, LMF lumefantrine, ATV atovaquone, PRG proguanil
aAllometry-scaled dose
b¼ of allometry-scaled dose
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Fig. 5 Toxicology of and humoral responses elicited by PbVac administration to NZW rabbits. a Schedule of parasite administration, sample
collection, and killing (arrows) in rabbits subjected to the bites of 100 non-infected (black horizontal line, 5 male and 5 female NZW rabbits for
each experimental group) or 100 PbVac-infected mosquitoes (orange horizontal line 5 male and 5 female NZW rabbits for each experimental
group). b, c “Vaccine take” illustrated by the amount of anti-PbCS repeats (b), anti-PfCS repeats (c) antibodies detected in serum samples of
mock-immunized and PbVac-immunized male and female rabbits, collected throughout the duration of the study (bars represent average of
all observations per time point and respective standard deviation). d Body weight of male and female rabbits throughout the duration of the
study. e Body temperature of male and female rabbits throughout the duration of the study. d, e Light and dark blue represent male rabbits
subjected to non-infected mosquito bites or PbVac-infected mosquito bites, respectively, and light and dark pink represent female rabbits
subjected to non-infected or PbVac-infected mosquito bites, respectively. Dots represent the average value of all animals within the group and
bars indicate the standard deviation
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mosquitoes to remove any contaminants that might have arisen
during prior manipulation of Pb and during the genetic
modiﬁcation procedures to produce PbVac. This MCB was
extensively analyzed and shown to be free of microbiological
contaminants. The determination of the parasite’s entire genomic
sequence and the comparison with the Pb reference sequence3
further conﬁrmed the correct modiﬁcation of the parental
parasite’s genome, as well as PbVac’s genetic homogeneity and
stability.
Although Pb has been employed as a model for malaria
research for decades, several gaps remain in our knowledge of its
behavior in permissive and non-permissive mammalian hosts. Pb
sporozoites are highly promiscuous and have been shown to
infect a wide range of host cell types in vitro using both CD81-
dependent and -independent invasion pathways.33 Thus, we have
established a parasite detection method that enables assessing
the presence of PbVac in a range of rabbit tissues, which ascertains
PbVac’s tropism for liver cells in a non-permissive host in vivo. The
clinical evaluation of the vaccine candidate is proposed to include
4 immunizations with PbVac, each delivered by 75 infected
mosquitoes. Because of this, we performed an extensive evalua-
tion of potential toxicity resulting from 5 consecutive administra-
tions of PbVac delivered to rabbits by 97 infective mosquito bites
each, ensuring 75 effective bites per administration. This study
revealed the absence of toxicity as a result of vaccine adminis-
tration, indicating the safety of its use in non-permissive human
hosts.
The data presented here show that the parasite is completely
eliminated from rabbits’ livers and all other organs analyzed up to
10 days after its administration. Additionally, our array of pre-
clinical results has shown that PbVac is unable to lead to a patent
blood stage infection in rabbits and is incapable of developing in
human erythrocytes.18 Nevertheless, the use of PbVac in the clinic
requires that safety measures are in place, in the unlikely event
that the parasite should persist in the human subjects’ liver or lead
to a patent blood stage infection in its human host. Malarone® has
been used in malaria prophylaxis for nearly 2 decades.34 It is a
combination of atovaquone and proguanil, two drugs that have
been shown to display causal prophylactic activity directed
against the liver stages of Pf35. Coartem®, which combines
artemether and lumefantrine, has been shown to display high
efﬁcacy in the treatment of uncomplicated,36 acute,37 and
multidrug-resistant38 Pf malaria, and to exert antimalarial activity
in a mouse model of Pb.39 Our results show that administration of
clinically relevant doses of Malarone® effectively clears hepatic
PbVac parasites, whereas clinically relevant doses of both
Malarone® and Coartem® fully abolish PbVac blood stage
parasitemia from infected mice. These results compound a solid
“safety net” that ensures the complete elimination of PbVac from
the patient organism in a clinical setting.
The present study constitutes a thorough assessment of a
rodent malaria parasite intended for human use. Our ﬁndings
elucidate novel aspects of the biology of Pb in permissive and
non-permissive hosts, providing further support for the laboratory
use of this parasite model. Crucially, they also address safety and
regulatory concerns regarding the use of PbVac in the clinic,
paving the way to the assessment of its safety and protective
efﬁcacy in Phase I/IIa clinical trials.
MATERIALS AND METHODS
Animals
All rodent experiments were carried out in male C57BL/6 or Balb/c mice
(from Charles River Laboratories), aged 6 to 10 weeks. Animals used for
blood passage were C57BL/6, older than 6 weeks. In each experiment, all
animals were matched by age. New Zealand White (NZW) rabbits were also
purchased from Charles River Laboratories. All animals were housed at the
animal facilities of the Instituto de Medicina Molecular (iMM Lisboa),
according to the guidelines of the Animal Care Committee of iMM Lisboa
(ACCiMM). All protocols involving live animals were approved by the
ACCiMM.
Parasites
Pb ANKA cl15cy1 was selected as the wild-type Pb (WT-Pb) line in the
current study. This parasite line derives from an isolate originally obtained
from Anopheles dureni millecampsi mosquitoes caught in the Democratic
Republic of Congo in 1965.40 Pb ANKA cl15cy1 was employed to generate
the Pb ANKA line 1596cl1,31 which served as the motherline for
the generation of PbVac18 by the ‘gene insertion / marker out’ (GIMO)
method. 31
Generation of master cell bank (MCB)
To generate a MCB of PbVac-infected red blood cells (iRBC), speciﬁc
pathogen free (SPF) Balb/c mice were infected by intraperitoneal injection
of 1.5 × 106 cryopreserved wild-type Pb- or PbVac-iRBC. Parasitemia and
parasite exﬂagellation were monitored daily. These mice were then
employed to infect Anopheles stephensi mosquitoes through 2 consecutive
days of mosquito bites. At ~7% parasitemia, blood was collected by heart
puncture, aliquoted and cryopreserved in liquid nitrogen until further use.
These vials contained PbVac-infected iRBC prior to cyclical propagation,
used in subsequent whole-genome sequencing studies (see below).
Twenty-one days after the blood meal, PbVac-infected A. stephensi
mosquitoes were allowed to feed on three naive SPF Balb/c mice.
Parasitemia and parasite exﬂagellation were monitored daily and these
were then employed to infect mosquitoes through two consecutive days
of mosquito bites. At ~6.5–8.5% parasitemia, blood was collected by heart
puncture, aliquoted and cryopreserved at −80 °C. This procedure was
repeated another two times, for a total of three passages of the PbVac
parasites through mosquitoes and four passages through SPF Balb/c mice.
Following the last passage through SPF Balb/c mice, blood was collected
by heart puncture when parasitemia was ~6.5%, aliquoted and cryopre-
served at −80 °C. Collected blood was further employed to infect 50 Balb/c
mice by intraperitoneal injection of PbVac-iRBC. When parasitemia in these
mice reached ~3%, the mice were killed and the blood was collected by
heart puncture and pooled. Two aliquots of this blood were collected for
microbiological analyses and whole-genome sequencing (see below). The
remaining blood was aliquoted and cryopreserved in liquid nitrogen,
constituting PbVac iRBC MCB (Fig. 1). The parental wild-type Pb parasites
underwent a similar procedure as that described for PbVac, enabling a
comparison of the genome sequences of both parasites before and after
cyclical propagation (see below). All Balb/c mice employed in this study
were purchased from Charles River Laboratories and had a certiﬁed SPF
health status.
Microbiological analyses of MCB samples
The ﬁnal batch of mice employed in MCB generation were further tested
for the full Federation for Laboratory Animal Science Associations (FELASA)
panel for SPF mice.41 One random mouse was sampled for every other
cage of 5 mice (5 samples from 10 cages). From each sampled mouse, 2–3
drops of blood were collected onto a paper sampling kit. Samples were
analyzed by IDEXX BioResearch using the FELASA 2014 Serology Panel,
which includes serologic evaluation for antibodies to Clostridium piliforme,
Mycoplasma pulmonis, Ectromelia, EDIM, LCMV, MAV1, MAV2, MHV, MNV,
MPV, MVM, PVM, REO3, Sendai, and TMEV (Table S1). Mouse fecal pellets,
oral swabs, and fur swabs were collected and tested in pools of samples
from 10 animals, as allowed per test sensitivity, according to the FELASA
2014 Bacteriology+ Parasitology Panel (Beta Strep Grp A PCR, Beta Strep
Grp B PCR, Beta Strep Grp C PCR, Beta Strep Grp G PCR, C. rodentium PCR,
C. kutscheri PCR, C. piliforme PCR, Helicobacter genus, M. pulmonis PCR, P.
pneumotropica-Heyl PCR, P. pneumotropica-Jawetz PCR, Salmonella Genus
PCR, S. moniliformis PCR, S. pneumoniae PCR, Cryptosporidium PCR,
Entamoeba PCR, Giardia PCR, Mite PCR, Pinworm PCR, and Spironucleus
muris PCR) by Charles River Laboratories (Table S1). Finally, MCB samples
were tested for possible human pathogens and adventitious viruses,
including arboviruses that could be transferred from the mosquitoes.
These analyses were performed by Charles River Laboratories and included
the Human Comprehensive CLEAR Panel [Adeno-associated virus, LCMV
PCR, Human cytomegalovirus, HANT (Hantavirus Hantaan) PCR, SEO
(Hantavirus) PCR, Hepatitis B virus, Hepatitis C virus, Epstein-Barr Virus,
Herpesvirus type 6, Herpesvirus type 7, Herpesvirus type 8, Mycoplasma
Genus PCR, HPV-16, HPV-18, Parvovirus B19, Hepatitis A virus, John
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Cunningham virus, BK virus, Human Foamy Virus, Human T-lymphotropic
virus, HIV-1, and HIV-2] (Table S2) and detection assays of adventitious
viruses by analysis of cytopathic effects (CPE), hemadsorption, and
hemagglutination in 28 day assays. These assays employed Vero (African
green monkey kidney, ECACC 84113001), MRC-5 (human embryonic lung,
ATCC CCL-771), NIH 3T3 (Swiss mouse embryo tissue, ECACC 93061524),
and BHK-21 (baby hamster kidney, ATCC CCL-10) indicator cell lines (Table
S2), and PI3 (parainﬂuenza virus type 3, ATCC VR-93), H1N1 virus (inﬂuenza
A virus, ATCC VR-219), Sindbis virus (ATCC VR-68), and vesicular stomatitis
virus (VSV, ATCC VR-158) as control viruses, respectively. The suitability of
the test method for its intended use was demonstrated in generic
validations according to International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for Human Use (ICH)
guidelines.
Whole-genome sequencing analyses
The whole genomes of wild-type Pb and PbVac collected prior to or
following cyclical propagation construction were sequenced at The Sanger
Institute, UK. Parasite DNA was extracted by phenol/chloroform extraction
following removal of leukocytes using a CF 11 column. The samples were
prepared as noPCR library.42 They were sequenced on a MiSeq with 150 bp
reads, aiming for a fragment length of 500 bp. The obtained reads were
aligned with Burrows-Wheeler Aligner’s Smith-Waterman Alignment (BWA-
SW)43 (parameter ‐a 1000, version 0.7.12 ‐r1039) and Bowtie244 (-X1000‐
very‐sensitive ‐N 1 ‐L 31 ‐rdg 5,2, version 2.1.0). The latest version of Pf 3D7
(version 3) and Pb ANKA (version 3) genomes from GeneDB,3,45 July 2015
version, were used as references. PCR duplicates were ﬂagged with Picard.
For variant calling, the bam ﬁles for the different samples were merged,
realigned with GATK realign, and variants were called with GATK variant
caller “UniﬁedGenotyp”. De novo assembly was performed with Velvet46
(parameter k‐mer: 81 (sample PbMP8 k-mer of 61 ‐exp_cov auto‐
ins_length 350 ‐ins_length_sd50 ‐cov_cutoff 5 ‐min_contig_lgth 500 ‐
min_pair_count 10; Version 1.2.07). Contigs were ordered and orientated
against the Pb genome using ABACAS2.47 Potential insertion sites
(including the target gene), potential recombination “not-proper paired”
reads, as well as differences between de novo assemblies, were searched
for. Detection of potential copy number variation (CNV) was performed
manually through the evaluation of changes in the read coverage.
Mouse infection and parasite synchronization for parasite
detection assays
All mice used in the parasite detection assays were infected intraper-
itoneally (i.p.) with PbVac, either with 1 × 106 fresh, infected red blood cells
(pRBCs) collected from a passage mouse previously infected from a frozen
vial (blood passage), or with 2 × 106 frozen pRBCs (infection with frozen
vial). Parasitemia in the inoculum (number of pRBCs / total number of RBCs
x 100) was assessed by microscopic evaluation of Giemsa-stained tail-
blood smears, by counting at least 2000 RBCs.
P. berghei is one of the few mammalian parasites whose schizonts do not
rupture spontaneously in vitro. This feature is the rational support behind
the parasite synchronization protocol described below, based on,48 which
results in most of the pRBCs being synchronized in the more mature stages
after overnight (o/n) incubation. Brieﬂy, infected mice were killed by CO2
inhalation and blood was collected by cardiac puncture, into 30ml of PBS.
Blood was then centrifuged at 650×g (without brake), for 10min at 4 °C.
The supernatant was discarded and the pellet carefully resuspended in
50ml of the culture medium solution (RPMI 1640, supplemented with 25%
FBS, 2mM L-Glutamine, penicillin–streptomycin at 50 μg/ml, 1% (v/v)
HEPES, 1% (v/v) non-essential amino-acids), before being divided into two
25 cm3 culture ﬂasks. Flasks were incubated at 37 °C under an atmosphere
of 5% O2, 5% CO2, 90% N2 for 12–16 h. After o/n incubation, mature pRBCs
were isolated by a density gradient. Brieﬂy, the RBC suspensions were
carefully pipetted on top of 10ml of a 65% (v/v) Nicodenz solution and
then centrifuged at 550×g, for 30 min at 21 °C (without brake). Most of the
upper layer was discarded and the interface between the upper layer and
the bottom layer was pipetted into a 50ml Falcon tube and PBS was added
up to a volume of 40ml. This cell suspension was centrifuged at 580×g, for
8 min (without brake) and the pellet was resuspended in 400 μl of PBS 1×.
Puriﬁed schizonts were then injected intravenously into the tail veins of
2–3 mice. Infected blood was collected either 3–4 h after injection of the
schizonts (ring forms from the ﬁrst cycle) or 24–26 h after injection of the
schizonts (ring forms from the second cycle). Parasitemia and percent of
synchronization (number of rings/ total number of parasites × 100) was
then assessed.
DNA extraction for parasite detection assays
Collected blood was washed three times with 20ml of RNAse/DNAse-free
PBS. The supernatant was discarded and the pellet was resuspended in
500 μl PBS. Parasiteamia was counted as described before; the number of
total RBCs was counted in a Neubauer chamber.
A series of tenfold dilutions of the infected blood in uninfected blood
from healthy mice with known baseline erythrocyte counts (around 4–5 ×
106 RBC/μl cell suspension) was prepared. The assay was then applied to
the detection of PbVac in human blood. To this end, PbVac-infected RBCs
were serially diluted in naive human blood and genomic DNA was
extracted and analyzed. Genomic DNA was isolated from 20 μl of blood
from every sample in the dilution series using the DNAeasy Blood and
Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions, following the Nonnucleated blood protocol. The DNA samples
were dissolved in 50 μl of elution buffer.
Parasite detection by quantitative real-time PCR
Parasite detection employed P. berghei 18S rRNA-speciﬁc primers. A
fragment of the P. berghei gene encoding the 18S ribosomal RNA subunit
was ampliﬁed by quantitative real-time PCR (qRT-PCR) using TaqMan
chemistry and hydrolysis probes. Probes were labeled with 6-carboxy-
ﬂuorescein (FAM) and with minor groove binding non-ﬂuorescent
quencher (MGB). For the qRT-PCR reaction, 4 μl of sample DNA was used
along with 250 nM probe, 300 nM of each primer, water, and 10 μl TaqMan
Universal Master Mix (Applied Biosystems, USA), in a total reaction volume
of 20 μl. The sequences for primers and TaqMan probe used are listed in
Table S3. Reactions were performed on the ABI Prism 7500 system (Applied
Biosystems) with the following cycling conditions: 50 °C for 2 min, initial
denaturation at 95 °C for 10min, then 40 cycles at 95 °C for 15 s, and 60 °C
for 1 min. Fluorescence data was collected during the annealing/extension
step at 60 °C. All qRT-PCR reactions were prepared in a laminar ﬂow hood
with ﬁltered pipette tips. All tests were performed in duplicate, and
samples were tested on plates that included appropriate negative
(reaction mixture without DNA and with DNA extracted from a healthy
mouse) and positive (plasmid and a known positive sample) controls.
External standardization was performed using plasmids encoding the full-
length 18S rRNA gene cDNA cloned in TOPO TA (Invitrogen).49 The
concentration of plasmid DNA was determined by spectrophotometry for
the calculation of the DNA copy number. For standard curve analysis in
real-time PCR assays, the plasmid was serially diluted tenfold in nuclease-
free water from 1010 copies to 10-5 copies per qRT-PCR reaction. The
efﬁciency (E) of the assay was calculated using the equation E= (10(−1/
slope))− 1 × 100.
Infection and sample collection for tissue distribution assays
NZW rabbits (5 rabbits per group; 3 males and 2 females) were infected by
the bites of 75 PbVac-infected A. stephensi mosquitoes and killed at 1 h,
48 h, and 10 days after infection. One control group (3 rabbits) of non-
infected rabbits was killed at the same time as the rabbits killed 10 days
after infection. The following tissues were collected and ﬂash frozen in
liquid nitrogen until further processing: bladder, blood, brain, epidermis (at
the site of administration), eye, heart, kidney, liver, lung, lymph node
(proximal to the site of administration), bone marrow, muscle (at the site of
administration), spleen, subcutis (at the site of administration), ovaries, and
testes.
Analysis of tissue distribution samples
A sample of each tissue was homogenized in denaturing solution (4 M
guanidine thiocyanate, 25 mM sodium citrate [pH 7], 0.5% N-
lauroylsarcosine in diethyl pyrocarbonate [DEPC]-treated water) supple-
mented with 0.1 M β-mercaptoethanol) using a minibead beater for tissue
disruption. RNA was extracted using TRIzol® (Ambion by Life Technolo-
gies), or TRIzol®LS (Ambion by Life Technologies) for blood samples,
according to the manufacturer’s instructions. After extraction, DNase I
treatment was performed with NzyTech’s DNase, according to the
manufacturer’s instructions. RNA was quantiﬁed using a NanoDrop
1000 spectrophotometer and cDNA was synthesized using the NZYTech
First-Strand cDNA synthesis kit. A fragment of the P. berghei gene encoding
the 18S ribosomal RNA subunit was ampliﬁed by qRT-PCR using TaqMan
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chemistry and hydrolysis probes. The qRT-PCR reaction was performed in a
total volume of 10 μl, containing 2 μl of sample cDNA, 250 nM TaqMan
Probe (1 μl), 300 nM of each primer (1 μl), RNase/DNase-free water (1 μl)
and 5 μl TaqMan Universal Master Mix (Applied Biosystems, USA). The
sequences for primers and TaqMan Probe used are listed in Table S3.
Reactions were performed on a ViiA 7 system (Applied Biosystems) with
the following conditions: 50 °C for 2 min, initial denaturation at 95 °C for
10min, then 40 cycles at 95 °C for 15 s, and 60 °C for 1 min. Fluorescence
data was collected during the annealing/extension step at 60 °C. All
experiments were performed in duplicate and samples were tested on
plates that included appropriate negative (reaction mixture with RNase/
DNase-free water instead of DNA) and positive (plasmid DNA and infected
mouse livers at 48 h post-infection) controls. External standardization was
performed as described above using tenfold serial dilutions of plasmid in
nuclease-free water from 1010 copies to 10-2 copies per qRT-PCR reaction.
The efﬁciency of the assay was calculated as described above. The
sensitivity of detection of the standard plasmid in the presence of brain,
heart, and lung tissue was further conﬁrmed by spiking samples containing
2 out of 20 μl of cDNA previously synthesized from 1 μg RNA extracted
from rabbit brain, heart, and lung tissues, and already identiﬁed as
TaqMan-negative for this gene, with ﬁve dilutions of the plasmid (103, 102,
101, 100, 10-1) prior to qRT-PCR and agarose gel electrophoresis analyses.
To conﬁrm the effectiveness of the extraction of parasite RNA in the
presence of rabbit tissues, 104 PbVac sporozoites were added to 200 μl
homogenates of rabbit brain, heart, and lung tissues, previously shown to
be TaqMan-negative for 18S-Pb. Total RNA was extracted from the mixture
and used to synthesize cDNA, which was analyzed by qRT-PCR using 18S-
Pb-speciﬁc primers and by agarose gel electrophoresis. In each agarose gel
image presented in the manuscript and Supplemental Information, all
samples derive from the analysis of the same biological specimen and
were processed in parallel.
Toxicology assays
A toxicology study was performed by the Radboud University Medical
Center and BioXpert B.V. in The Netherlands, under a project license
granted by the Central Committee for Animal Experiments (CCD in Dutch)
and the Animal Experiments Committee (DEC) consult (project license
AVD905002015183). The study was conducted in 24-week-old male and
female NZW rabbits (Envigo). Animals were SPF at delivery and were kept
to maintain SPF status through monitoring and conﬁrmation by
microbiological health screening. All mosquitoes employed in the study
were A. stephensi produced at the Radboud University Medical Center in
Nijmegen, and were transported to the BioXpert B.V. Prior to immunization
by mosquito bites, animals were sedated with medetomidine (Dexdomitor)
and the application sites (i.e., ﬂank) were shaved. A pilot study was initially
performed in 5 animals subjected to the bites of 100 wild-type Pb-infected
mosquitoes, to determine the mosquito feeding rate and to ascertain the
impact of the medetomidine sedation on the latter. Our results showed
that the mosquito feeding rate was 80.5% and was unaffected by
medetomidine, whereas the mosquito mortality rate on the immunization
day itself was estimated at ~4%. Thus, it was determined that the
containers on the main study should contain 97 mosquitoes in order to
attain the target dosage of 75 mosquito bites per immunization proposed
for the evaluation of PbVac in the main study. Forty rabbits, 19 males and
21 females, were randomly assigned to the “infected” group or
“uninfected, control” group for a total of 5 exposures to the bites of 97
PbVac-infected mosquitoes or 97 non-infected mosquitoes per rabbit,
respectively, at Study Days (SD) 0, 14, 28, 42, and 56. Blood samples were
collected from the marginal ear veins or saphenic veins without sedation.
Samples for immunological analyses were collected on the day of each
immunization and at euthanasia; samples for clinical chemistry, hematol-
ogy, and coagulation analyses were collected on the day of immunization,
2 and 4 days after immunization, and at euthanasia. Animals were killed 3
(acute phase) or 28 (recovery phase) days after the last immunization with
the mosquitoes. During the in-life phase, the effect of PbVac was evaluated
by cage side observations, clinical examinations, body weight and daily
food intake, body temperature, dermal draize observation, and ophthal-
mologic examination. The evaluations performed at necropsy included
macroscopic examinations of the external surface of the body, all oriﬁces,
injection sites, the cranial, thoracic, and abdominal cavities, and their
contents; hematology of bone marrow; determination of organ weights;
and macroscopic and microscopic examination of putative gross lesions.
Full panels of clinical chemistry and hematology on collected samples
were performed by IDEXX Europe B.V. (Hoofddorp, The Netherlands). The
post-mortem histopathological evaluation of organs was performed by
Charles River Laboratories Den Bosch B.V. (‘s-Hertogenbosch, the
Netherlands).
Statistical analyses were conducted to evaluate effect of immunization
with infected mosquitoes. For body weight, body temperature, and dermal
draize analyses, a Shapiro–Wilk normality test was initially performed to
assess whether or not data were normally distributed. Body weight and
body temperature were analyzed using a one-sample t-test, compared to
the mean body weight on day 0 and mean body temperature on day −1
(i.e., 39.2 °C). Dermal draize scores were analyzed using a Wilcoxon signed-
rank test. For analyses of clinical chemistry, coagulation, and hematology
data, boxplots of all relevant parameters were made. Values of parameters
that were below the detection limit were excluded (i.e., values of
cholesterol, gamma-glutamyl transpeptidase, and total bilirubin). Subse-
quently, outliers per group were identiﬁed and excluded. Statistical
comparison has been conducted by one-way analysis of variance (ANOVA)
on multi-groups followed by Dunnett’s multiple comparison test if a
signiﬁcant difference was discerned. Furthermore, it was assessed whether
or not the mean ± SD per time point was outside the normal range for
rabbits. All statistical analyses have been conducted as two-sided tests
with a level of signiﬁcance of p < 0.05. For analyses of organ weights, the
mean ± SD per organ was compared to their respective control using one-
way ANOVA and/or t-test.
ELISA
High protein-binding capacity 96 well enzyme-linked immunosorbent
assay (ELISA) plates (Nunc MaxiSorp™ ﬂat-bottom) were coated with
synthetic peptide (Sigma) based on the repeat region of the PfCS protein
with the amino acid sequence (NANP)4NVDPC, or the repeat region of the
PbCS protein with the amino acid sequence (DPPPPNPN)2. The peptide
was coated overnight at 4 °C at a concentration of 5 µg/ml in a volume of
50 µl per well. Plates were washed three times with PBS containing 0.1% (v/
v) Tween-20 and blocked with 200 µl PBS containing 0.1% (v/v) Tween-20
and 1% (w/v) BSA for 30min at room temperature. Plates were washed one
additional time and samples serially diluted in PBS containing 0.1% (v/v)
Tween-20 and 1% (w/v) BSA were added and incubated at 22 °C for 2 h.
After washing four times, horseradish peroxidase-labeled goat anti-rabbit
IgG (GE Healthcare UK) was added at a dilution of 1:2000 and incubated at
22 °C for 1 h. BD OptEIA™ TMB Substrate Reagent was then added for
development and incubated for 1 to 3min at 22 °C before stopping the
reaction by adding 50 µl Stop solution (2 N H2SO4). The Optical density was
determined using a microplate reader (Inﬁnite M200). To serve as a positive
control and to allow comparison between samples from different assays, a
standard titration curve of at least 8 points, starting a dilution of 1/20 of a
pool of rabbit sera from all immunized animals, was used as reference in all
assays.
Drug sensitivity assays
Drug sensitivity assays employed clinically relevant drug doses and
schedules of administration as deﬁned by the Centers for Disease Control
and Prevention’s Guidelines for Treatment of Malaria in the United States
for Malarone® and chloroquine (http://www.cdc.gov/malaria/resources/
pdf/treatmenttable.pdf), and by Novartis’s Highlights of Prescribing
Information for Coartem® (https://www.pharma.us.novartis.com/product/
pi/pdf/coartem.pdf). Drug doses in mice were calculated based on
allometric scaling, employing the formula: Allometric-scaled dose in
humans=mice dose * (weight human/weight mice)0.75 50
To avoid atovaquone toxicity in mice, ¼ of the allometric-scaled dose of
Malarone® was employed in the study.
For liver stage drug sensitivity assays for Malarone®, C57Bl/6 mice were
infected by the bites of 20 PbVac-infected A. stephensi mosquitoes,
followed by 3 administrations at 18-h intervals of the same dose of
Malarone as that employed in the blood stage-clearance study (see below).
PbVac-infected mice employed as controls were left untreated. Forty-six
hours after sporozoite administration, mice were killed and liver parasite
load was assessed by qRT-PCR as previously described.51
Blood stage drug sensitivity assays for Malarone®, chloroquine, and
Coartem® were performed on Balb/c mice. Human doses, allometry-scaled
mouse doses, and administration schedules employed, are listed in Table 1.
Mice were infected by intraperitoneal injection of 2 × 106 PbVac-infected
red blood cells. Blood parasitemias were monitored daily by microscopy
analysis of Giemsa-stained blood smears. Treatment was initiated at two
distinct moments, in different groups of mice, either at patency, as
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determined by blood smear analysis, or at ~1.5% parasitemia, as
determined by blood smear analysis. Compounds were administered per
os by oral gavage. Negative control mice were treated with an equivalent
amount of drug vehicle, administered in a schedule equivalent to that of
the drugs of interest. Positive control mice were treated by daily
intraperitoneal injection of 0.7 mg chloroquine. During and after treatment,
disease symptoms and parasitemia were monitored daily. If a treatment
cleared the parasites from circulation, parasitemia was monitored for an
additional 30 days until parasite clearance could be deﬁnitely established.
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